As of September 18, 2026, ONESOURCE is trading at ₹1594.9, with a daily technical stance indicating a potential shift. While the daily timeframe shows the price above several key moving averages (EMA 20, EMA 50, SMA 20, SMA 200, SMA 50), the Supertrend indicator is bearish, suggesting short-term caution. This contrasts with the weekly timeframe, where the Supertrend is bullish, though the price is below its EMA 20, EMA 50, SMA 20, and SMA 50. The monthly timeframe presents a mixed picture, with the price above its EMA 20 but below its SMA 20 and Supertrend, which is also bearish. Recent market activity includes two positive attention events and one neutral event in the last 30 days, alongside an upward gap on September 15, 2026. The stock is currently positioned within its recent trading range, closer to the lower end based on 50-day and 252-day ranges.

The nearest support level is identified at ₹1590.47, approximately 0.28% below the current price. Resistance is observed at ₹1611.33, about 1.03% higher. The stock exhibits an annualized volatility of 44% and a current drawdown of -27%. A notable anomaly occurred on September 9, 2026, with extreme volume accompanying a price decrease, and another on September 8, 2026, with extreme volume and a price increase. A "Harami" pattern was active on the monthly timeframe as of September 18, 2026.

Key watch conditions include monitoring the price action around the ₹1590.47 support level. A break below this could signal further downside. Conversely, a sustained move above the ₹1611.33 resistance level, especially with increasing volume, would be a positive development. The conflicting signals between the daily and longer-term timeframes suggest a period of consolidation or transition, making close observation of price action crucial.

Onesource Specialty Pharma Limited provided updates regarding its upcoming 19th Annual General Meeting (AGM) scheduled for September 23, 2026. An addendum to the AGM notice, issued on September 11, 2026, disclosed additional details on material related party transactions with Strides Pharma Science Limited and its US subsidiary, specifically concerning agenda items 6 and 7. The company also confirmed that the Audit Committee has reviewed the necessary CEO/CFO certificates for these transactions. Earlier, on September 1, 2026, Onesource Specialty Pharma announced the publication of newspaper advertisements confirming the dispatch of the AGM notice and remote e-voting information. The company's 19th AGM will review the Integrated Annual Report for the financial year ending March 31, 2026, during which the company reported revenue of ₹14,216 million and adjusted profit after tax of ₹739 million. Additionally, Onesource Specialty Pharma committed approximately US$80 million towards expanding its cartridge manufacturing capacity as part of a planned US$100 million capital expenditure program and received in-principle approval for incentives worth approximately ₹70 crore under the Karnataka Industrial Policy 2025–30. The company also completed a statutory auditor rotation, appointing BSR (KPMG) to replace Deloitte.

In parallel, Onesource Specialty Pharma engaged with investors, holding an investor presentation on September 3, 2026, at its manufacturing facility in Doddaballapura, Bengaluru. This event followed a scheduled physical group investor meeting on the same date, where representatives discussed publicly available information on business overview, strategy, and industry trends. The company uploaded its latest investor presentation to its website following these engagements.

As of September 18, 2026, Onesource Specialty Pharma (NSE: ONESOURCE) saw a modest increase in its stock price, moving from ₹1580.0 to ₹1594.9. This change occurred on the observation date of September 18, 2026. No new filings or news developments were reported for the company in the period leading up to this date. The company's profile on the NSE remains unchanged.

OneSource Specialty Pharma Limited has provided updates regarding its upcoming 19th Annual General Meeting (AGM) scheduled for September 23, 2026. An addendum to the AGM notice, filed on September 11, 2026, disclosed additional information on material related party transactions with Strides Pharma Science Limited and its US subsidiary, pertaining to agenda items 6 and 7. The company also published newspaper advertisements on September 1, 2026, confirming the dispatch of AGM notices and remote e-voting information. Earlier, on August 31, 2026, the company announced its 19th AGM date and provided financial highlights for the fiscal year ending March 31, 2026 (FY26). During FY26, OneSource reported revenue of ₹14,216 million and adjusted profit after tax of ₹739 million. The company committed approximately US$80 million of a planned US$100 million capital expenditure towards expanding cartridge manufacturing capacity and received in-principle approval for incentives worth approximately ₹70 crore under the Karnataka Industrial Policy 2025–30. Additionally, the company completed a statutory auditor rotation from Deloitte to BSR (KPMG). The Business Responsibility & Sustainability Report for FY26, filed on August 31, 2026, detailed a standalone paid-up capital of ₹11.46 crore, a turnover of ₹14,204 million (70.80% from exports), and a workforce of 995 permanent workers and 188 employees as of FY26. Operational metrics included ISO certifications for quality, safety, environment, and information security. On August 17, 2026, India Ratings & Research upgraded the company's long-term bank loan facilities rating to 'IND A' with a positive outlook, reflecting a transition to a commercial supply-led model. The company reported strong Q1 FY27 performance on July 31, 2026, with revenues of INR 4,490 million (up 37% year-on-year) and EBITDA of INR 1,233 million (up 39% year-on-year), driven by a semaglutide launch and nearing completion of its capital expenditure program. Preeti Kalra was designated as Senior Management Personnel effective July 24, 2026, while Ravi Kumar resigned from his SMP position on the same date.

Onesource Specialty Pharma (NSE) has shown a notable shift in its operating performance, moving from losses to profitability. Revenue from operations increased sequentially, reaching ₹449.02 crore in Q1 FY2026-27 from ₹428.22 crore in Q4 FY2025-26. This revenue growth has coincided with a turnaround in profitability. After reporting losses in Q3 FY2025-26 (₹-88.70 crore Profit Loss For Period) and a marginal profit in Q4 FY2025-26 (₹4.60 crore Profit Loss For Period), the company posted a profit of ₹25 crore for Q1 FY2026-27. This improvement is also reflected in the earnings per share, which moved from a loss of ₹-7.74 per share in Q3 FY2025-26 to ₹2.18 per share in Q1 FY2026-27. The company's ability to translate revenue growth into profit is a key area to monitor, especially given the fluctuating tax expenses observed across the periods.

The company's stock is showing some constructive signals on a weekly basis, with the Supertrend indicator suggesting a bullish trend as of September 18, 2026. While the daily and monthly trends are currently indicated as bearish, the weekly timeframe indicates potential for upward movement. The stock's closing price of ₹1594.9 is trading above its 20-day Exponential Moving Average (EMA) of ₹1566.21, and the EMA itself is showing a positive slope, which can be interpreted as short-term positive momentum. Additionally, the stock has experienced positive returns over shorter periods, including a 3.0% return in the last month and a 7.7% return over the last six months. However, it is important to note that the stock has experienced a year-to-date return of -11.0% and a 1-year return of -14.0%, indicating a longer-term downward trend. The current price is also approaching a near-term resistance level at ₹1611.33, which is 1.03% above the current price.

Onesource Specialty Pharma's technical indicators suggest a cautious outlook. The monthly trend shows a bearish Supertrend at ₹2375.47, indicating a longer-term downward pressure. While the weekly trend has a bullish Supertrend at ₹1355.1, the weekly 20-day and 50-day Simple Moving Averages (SMAs) are sloping downwards, with the 50-day SMA slope at -27.73 and the 20-day SMA slope at -7.86. The stock is trading below its 20-day and 50-day SMAs on a weekly basis. Daily indicators present a mixed picture, with a bearish Supertrend at ₹1650.57, but the 20-day Exponential Moving Average (EMA) slope is positive at 17.0. The stock is currently trading slightly above its 20-day EMA (₹1566.21) and 50-day SMA (₹1589.17), but below its 200-day SMA (₹1581.67). The company has experienced a year-to-date return of -11% and a 1-year return of -14%. Its current drawdown stands at -27%, with a maximum drawdown of -49% observed historically.